Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Meihao Medical (301363), indicating a decline in stock price and mixed financial results [1][2]. - As of February 5, 2026, Meihao Medical's stock closed at 31.39 yuan, down 1.97%, with a turnover rate of 2.74% and a trading volume of 102,200 hands, resulting in a transaction amount of 323 million yuan [1]. - The net capital outflow from major funds was 17.27 million yuan, accounting for 5.35% of the total transaction amount, while retail investors saw a net inflow of 28.65 million yuan, representing 8.88% of the total transaction amount [1]. Group 2 - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, but a net profit attributable to shareholders of 208 million yuan, which is a year-on-year decrease of 19.25% [2]. - The third quarter of 2025 showed a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, reflecting a year-on-year increase of 5.89% [2]. - The company has a debt ratio of 11.43%, with investment income of 4.90 million yuan and financial expenses of -27.39 million yuan, while maintaining a gross profit margin of 39.34% [2]. Group 3 - In the last 90 days, seven institutions have given buy ratings for Meihao Medical, with an average target price of 24.57 yuan [3]. - The article explains the concept of capital flow, indicating that capital inflow is defined by the transaction amount from active buy orders when stock prices are rising, while capital outflow is defined by the transaction amount from active sell orders when stock prices are falling [3].
股票行情快报：美好医疗（301363）2月5日主力资金净卖出1727.19万元